Furthermore, we observed that Reversan inhibited both anchorage-dependent (Figure 5A) and anchorage-independent (Figure 5B) growth of HiMYC cells, a prostate cancer cell line derived from a mouse model that is genetically engineered to exhibit prostatic intraepithelial neoplasia and invasive malignancy upon overexpression of c-MYC [18]. Here, MYC is linked to prostate cancer.